Transcranial AC Pulsed Applications of Weak Electromagnetic Fields Reduces Freezing and Falling in Progressive Supranuclear Palsy: A Case Report

References

• Aldegunde M., Miguez I., Veira J. Effects of pinealcctomy on regional brain serotonin metabolism. International Journal of Neuroscience 1985; 26: 9–13
   PubMed Web of Science ®Google Scholar
• Antolin I., Rodriguez C., Sainz R. M., Mayo J., Uria H., Kotler M. L., Rodriguez-Colunga M. J., Tolivia D., Menedez-Pelaez A. Neurohormone melatonin prevents cell damage: effect on gene expression for antioxidant enzymes. FASEB Journal 1996; 10: 882–890
   PubMed Web of Science ®Google Scholar
• Anton-Tay F., Diaz J. L., Fernandez-Guardiola A. On the effects of melatonin upon human brain. Its possible therapeutic implications. Life Sciences 1971; 10: 841–850
   Web of Science ®Google Scholar
• Barlow-Walden L. R., Reiter R. J., Abe M., Pablos M., Menendez-Pelaez A., Chen L. D., Poeggeler B. Melatonin stimulates brain glutathione peroxidase activity. Neurochemistry International 1995; 26: 497–502
   PubMed Web of Science ®Google Scholar
• Barr A. N. Progressive supranuclear palsy. Handbook of clinical neurology: extrapyramidal disorders, P. J. Vinken, G. W. Bruyn, H. L. Klawans. Elsevier Science Publishers, Amsterdam 1986; 239–254
   Google Scholar
• Bawin S. M., Adey W. R. Sensitivity of calcium binding in cerebral tissue to weak environmental electrical fields oscillating at low frequency. Proceedings of the National Academy of Sciences, USA 1976; 73: 1999–2003
   PubMed Web of Science ®Google Scholar
• Bawin S. M., Gavalas-Medici R. J., Adey W. R. Effects of modulated very high frequency fields on specific brain rhythms in cats. Brain Research 1973; 58: 365–384
   PubMed Web of Science ®Google Scholar
• Bell G., Marino A., Chesson A., Struve F. Electrical states in the rabbit brain can be altered by light and electromagnetic fields. Brain Research 1992; 570: 307–315
   PubMed Web of Science ®Google Scholar
• Blackman C. F., Benane S. G., Kinney L. S., House D. E., Joines W. T. Effect of ELF fields on calcium-ion efflux from brain tissue in vitro. Radiation Research 1982; 92: 510–520
   PubMed Web of Science ®Google Scholar
• Bliss V. L., Heppner F. H. Circadian activity rhythms influenced by near zero magnetic field. Nature 1976; 261: 411–412
   PubMed Web of Science ®Google Scholar
• Bokobza B., Ruberg M., Scatton B. 3H-spiperone binding, dopamine and HVA concentrations in Parkinson's disease and supranuclear palsy. European Journal of Pharmacology 1984; 99: 167–175
   PubMedGoogle Scholar
• Bradbury A. J., Kelly M. E., Smith J. A. Melatonin action in the mid-brain can regulate dopamine function both behaviourally and biochemically. The pineal gland: endocrine aspects, G. M. Brown, S. D. Wainwright. Pergamon Press, Oxford 1985; 327–332
   Google Scholar
• Burton S., Daya S., Potgieter B. Melatonin modulates apomorphine induced rotational behaviour. Experientia 1991; 47: 466–469
   PubMedGoogle Scholar
• Cotzias G. C., Tang L. C., Miller S. T., Ginos J. Z. Melatonin and abnormal movement induced by L-dopa in mice. Science 1971; 173: 450–452
   PubMed Web of Science ®Google Scholar
• D'Antona R., Baron J. C., Samson Y., Serdaru M., Viader F., Cambier J. Subcortical dementia-frontal cortex hypometabolism detected by positron tomography in patients with progressive supranuclear palsy. Brain 1985; 108: 785–799
   PubMed Web of Science ®Google Scholar
• Culebras A. Clinical handbook of sleep disorders. Butterworth-Heinemann, Boston 1996; 259–260
   Google Scholar
• David N. J., Mackey E. A., Smith J. L. Further observations in progressive supranuclear palsy. Neurology 1968; 18: 349–356
   PubMed Web of Science ®Google Scholar
• Delwaide P. J., Gonce M. Pathophysiology of Parkinson's signs. Parkinson's disease and movement disorders, J. Jankovic, E. Tolosa. Urban & Schwarzenberg, Baltimore 1988; 59–73
   Google Scholar
• Fahn S. Parkinsonism. Merrit's textbook of neurology, 9th edition, L. P. Rowland. Williams & Wilkins, Baltimore 1995; 713–728
   Google Scholar
• Fahn S., Cohen G. The oxidant stress hypothesis in Parkinson's disease: evidence supporting it. Annals of Neurology 1992; 32: 804–812
   PubMed Web of Science ®Google Scholar
• FitzGerald P. M., Jankovic J. Lower body Parkinsonism: evidence for vascular etiology. Movement Disorders 1989; 4: 249–260
   PubMed Web of Science ®Google Scholar
• Foster M. L., Aldrich M. S., Bluemlin L., White R. F., Berent S. Failure of cholinergic agonist RS-86 to improve cognition and movement in PSP despite effects on sleep. Neurology 1989; 39: 257–261
   PubMedGoogle Scholar
• Gearing M., Olson D. A., Watts R. L., Mirra S. S. Progressive supranuclear palsy: neuropathology and clinical heterogeneity. Neurology 1994; 44: 1015–1024
   PubMed Web of Science ®Google Scholar
• Gerstmann J., Schilder P. Ueber eine besondere Gangstoerung beim Stirnhirnerkrankung. Wien Medizinisehe Wochenschrift 1926; 76: 97–102
   Google Scholar
• Ghika J., Tennis M., Hoffman E., Schoenfeld D., Growdon J. Idazoxan treatment in progressive supranuclear palsy. Neurology 1991; 41: 986–991
   PubMed Web of Science ®Google Scholar
• Giladi N., Kao R., Fahn S. Freezing phenomenon in patients with Parkinsonian syndromes. Movement Disorders 1997; 12: 302–305
   PubMed Web of Science ®Google Scholar
• Giusti P., Gusella M., Lipartiti M., Milani D., Zhu W., Vicini S., Manev H. Melatonin protects primary cultures of cerebellar granule neurons from kainate but not from N-Methyl-D-Aspartate excitotoxicity. Experimental Neurology 1995; 131: 39–46
   PubMed Web of Science ®Google Scholar
• Golbe L. I., Davis P. H. Progressive supranuclear palsy. Recent advances. Parkinson s disease and movement disorders, J. Jankovic, E. Tolosa. Urban & Schwarzenberg, Baltimore 1988; 121–130
   Google Scholar
• Golbe L. I., David P. H., Schoenberg B. S., Duvoisin R. C. Prevalence and natural history of progressive supranuclear palsy. Neurology 1988; 38: 1021–1034
   Google Scholar
• Imai H. Frozen gait in Parkinson's disease. Neurology Medical Chirurgie (Tokyo) 1976; 4: 309–318
   Google Scholar
• Imai H., Narabayashi H. Akinesia - concerning 2 cases of pure akinesia. Shinkei Xenkyu Shimpo 1974; 18: 787–794
   Google Scholar
• Jackson J. A., Jankovic J., Ford J. Progressive surpranuclear palsy: clinical features and responses to treatment in sixteen patients. Annals of Neurology 1983; 13: 273–278
   PubMed Web of Science ®Google Scholar
• Jankovic J. Treatment of Parkinson's disease and progressive supranuclear palsy: a controlled trial of pergolide mesylate. Neurology 1982; 32: 182
   Google Scholar
• Jellinger K., Riederer P., Tomonga M. Progressive supranuclear palsy: clinical-pathological and biochemical studies. Journal of Neural Transmission 1980; 16: 111–128
   Google Scholar
• Kanazawa I. Clinical pathophysiology of basal ganglia disease. Handbook of clinical neurology: extrapyramidal disorders, P. J. Vinken, G. W. Bruyn, H. L. Klawans. Elsevier, Amsterdam 1986; 5: 65–85, (49)
   Google Scholar
• Karabakhtsian R., Broude N., Shalts N., Kochlatyi S., Goodman R., Henderson A. S. Calcium is necessary in the cell response to EM fields. FEBS Letters 1994; 349: 1–6
   PubMed Web of Science ®Google Scholar
• Kaczmarek L., Adey W. Weak electric gradient change ionic and transmitter fluxes in cortex. Brain Research 1974; 66: 537–540
   Web of Science ®Google Scholar
• Kienzl E., Riederer P., Jellinger K., Wesemann W. Transitional states of central serotonin receptors in Parkinson's disease. Journal of Neural Transmission 1981; 51: 113–122
   PubMed Web of Science ®Google Scholar
• Kish S. J., Chang L. J., Mirchandani L., Shannak K., Hornykiewicz O. Progressive supranuclear palsy: relationship between extrapyramidal disturbances, dementia, and brain neurotransmitter functions. Annals of Neurology 1985; 18: 530–536
   PubMed Web of Science ®Google Scholar
• Klawans H. L., Ringel S. P. Observations on the efficiency of L-dopa in progressive supranuclear palsy. European Neurology 1971; 5: 115–129
   PubMedGoogle Scholar
• Koller W. C. Handbook of Parkinson s disease. Marcel-Dekker, Inc, New York 1987; 482–488
   Google Scholar
• Koller W. C., Morantz R., Vetere-Overfield B., Waxman M. Autologous adrenal medullary transplant in progressive supranuclear palsy. Neurology 1989; 3: 1066–1068
   Google Scholar
• Kopp N., Claustrat B., Tappaz M. Evidence for the presence of melatonin in the human brain. Neuroscience Letters 1980; 19: 237–242
   PubMed Web of Science ®Google Scholar
• Kristensen M. Progressive supranuclear palsy, 20 years later. Acta Neurologica Scandinavica 1985; 71: 177–189
   PubMedGoogle Scholar
• Lees A. J. The Steele-Richardson Olszewski syndrome (progressive supranuclear palsy). Movement disorders, C. D. Marsden, S. Fahn. Butterworth, London 1987; 272–289
   Google Scholar
• Mahler E. R., Lees A. J. The clinical features and natural history of progressive supranuclear palsy. Neurology 1986; 36: 1005–1009
   PubMedGoogle Scholar
• Manev J., Uz T., Kharlamov A., Joo J. Y. Increased brain damage after stroke or excitotoxie seizures in melatonin-deficient rats. FASEB Journal 1996; 10: 1546–1551
   PubMed Web of Science ®Google Scholar
• Markstein R. Neurochemical effects of some ergot derivatives: a basis for their antiparkinsonian actions. Journal of Neural Transmission 1981; 51: 39–59
   PubMedGoogle Scholar
• Marsden C. D. ‘On-Off’ phenomenon in Parkinson's disease. Parkinson's disease-current progress, problems and management, U. K. Rinne, M. Klinger, G. Stamm. Elsevier/North-Holland Biomedical Press, Amsterdam 1980; 241–254
   Google Scholar
• Marsden C. D., Parkes J. D. “On and Off” variability and response swings in Parkinson's disease. Research progress in Parkinson's disease, F. C. Rose, R. Capildeo. Pitman Medical, Kent 1980; 265–274
   Google Scholar
• Matsuo H., Takashima H., Kishikawa M. Pure akinesia: an atypical manifestation of progressive supranuclear palsy. Journal of Neurology, Neurosurgery and Psychiatry 1991; 54: 397–400
   PubMed Web of Science ®Google Scholar
• Mestre D., Blin O., Serratrice G. Contrast sensitivity is increased in a case of nonparkinsonian freezing gait. Neurology 1992; 42: 189–194
   PubMed Web of Science ®Google Scholar
• Miguez J. M., Martin F., Aldegunde M. Long-term pinealectomy alters hypothalamic serotonin metabolism in the rat. Journal of Pineal Research 1991; 11: 75–79
   PubMed Web of Science ®Google Scholar
• Milner B. Some effects of frontal lobectomy in man. The frontal granular cortex and behavior, J. M. Warren, K. Akert. McGraw-Hill, New York 1964; 313–334
   Google Scholar
• Montplaisir J., Petit D., Decary A., Masson H., Bedard M. A., Panisset M., Remillard G., Gauthier S. Sleep and quantitative EEG in patients with progressive supranuclear palsy. Neurology 1997; 49: 999–1003
   PubMedGoogle Scholar
• Nagasaki H., Kosaka K., Nakamura R. Distribution of rhythm formation in patients with hemisperic lesion. Tohoku Journal of Experimental Medicine 1981; 135: 231–236
   PubMed Web of Science ®Google Scholar
• Narabayashi H., Kondo T., Hayashi A. L-threo-3,4 -dihydroxyphenylserine treatment for akinesia and freezing of Parkinsonism. Proceedings of the Japanese Academy 1981; 57: 351–354
   Google Scholar
• Narabayashi H., Kondo T., Nagatsu T. L-threo-3.4 -dihydroxyphenylserine treatment for freezing and akinesia in Parkinsonism. Neurology 1982; 32: A180
   PubMed Web of Science ®Google Scholar
• Narabayashi H., Kondo T., Nagatsu T., Hayashi A., Suzuki T. DL-threo, 3,4-dihydrophenylserine for freezing symptom in Parkinsonism. Advances in Neurology 1984; 40: 497–502
   PubMedGoogle Scholar
• Neophytides A., Lieberman A. N., Goldstein M., Gopinathan G., Leibowitz M., Bock J., Walker R. The use of lisuride, a potent dopamine and serotonin agonist, in the treatment of progressive supranuclear palsy. Journal of Neurology, Neurosurgery and Psychiatry 1982; 45: 261–263
   PubMed Web of Science ®Google Scholar
• Niles L. P., Brown G. M., Mishra R. K. Effect of blinding and pinealectomy on regional brain monoamine concentrations. Journal of Neuroscience Research 1983; 10: 53–60
   PubMed Web of Science ®Google Scholar
• Pazo J. H. Effects of melatonin on spontaneous and evoked neuronal activity in the mesencephalic reticular formation. Brain Research Bulletin 1979; 4: 727–730
   Web of Science ®Google Scholar
• Rafal R. D., Grimm R. J. Progressive supranuclear palsy: functional analysis of the response to methylsergide and antiparkinsonian agents. Neurology 1981; 31: 1507–1518
   PubMed Web of Science ®Google Scholar
• Reiter R. J. Static and extremely low frequency electromagnetic field exposure: reported effects on the circadian production of melatonin. Journal of Cellular Biochemistry 1993; 51: 394–403
   PubMed Web of Science ®Google Scholar
• Reiter R. J. Oxidative processes and antioxidative defense mechanism in the aging brain. FASEB Journal 1995; 9: 526–533
   PubMed Web of Science ®Google Scholar
• Riley D. E., Fogt N., Leigh R. J. The syndrome of ‘pure akinesia’ and its relationship to progressive supranuclear palsy. Neurology 1994; 44: 1025–1029
   PubMed Web of Science ®Google Scholar
• Rosen A. D. Magnetic field influence on acetylcholine release at the neuromuscular junction. American Journal of Physiology 1992; 262: C1418–C1422
   PubMed Web of Science ®Google Scholar
• Rosen A. D., Lubowsky J. Magnetic field influence on central nervous system function. Experimental Neurology 1987; 95: 679–687
   PubMed Web of Science ®Google Scholar
• Ruberg M., Javoy-Agid F., Hirsch E., Scatton B., L'Heureux R., Hauw J. J., Duyckaerts C., Gray F., Morel-Maroger A., Rascol A., Serdaru M., Agid Y. Dopaminergic and cholinergic lesions in progressive supranuclear palsy. Annals of Neurology 1985; 18: 523–529
   PubMedGoogle Scholar
• Rudolph K., Wirz-Justice A., Krauchi K., Feer H. Static magnetic fields decrease nocturnal pineal CAMP in the rat. Brain Research 1988; 446: 159–160
   PubMed Web of Science ®Google Scholar
• Sallanon M., Claustrat B., Touret M. Presence of melatonin in various cat brainstem nuclei determined by radioimmunoassay. Acta Endocrinological 1982; 101: 161–165
   PubMedGoogle Scholar
• Sandyk R. Weak magnetic fields as a novel therapeutic modality in Parkinson's disease. International Journal of Neuroscience 1992a; 66: 1–15
   PubMed Web of Science ®Google Scholar
• Sandyk R. Magnetic fields in the therapy of Parkinsonism. International Journal of Neuroscience 1992b; 66: 209–235
   PubMed Web of Science ®Google Scholar
• Sandyk R. A drug naive Parkinsonian patient successfully treated with electromagnetic fields. International Journal of Neuroscience 1994a; 79: 99–110
   PubMed Web of Science ®Google Scholar
• Sandyk R. Treatment of Parkinson's disease with magnetic fields reduces the requirement for antiparkinsonian medications. International Journal of Neuroscience 1994b; 74: 191–201
   PubMedGoogle Scholar
• Sandyk R. Freezing of gait in Parkinson's disease is improved by treatment with weak electromagnetic fields. International Journal of Neuroscience 1996; 85: 111–124
   PubMed Web of Science ®Google Scholar
• Sandyk R. Treatment with AC pulsed electromagnetic fields improves the response to levodopa in Parkinson's disease. International Journal of Neuroscience, (in press)
   Web of Science ®Google Scholar
• Selby G. Clinical features. Parkinson's disease, G. M. Stern. Chapman and Hall Medical, London 1990; 349–353
   Google Scholar
• Semm P. Neurological investigations on the magnetic sensitivity of the pineal gland in rodents and pigeons. Comparative Biochemistry and Physiology 1983; 76A: 683–689
   Web of Science ®Google Scholar
• Steele J. C., Richardson J. C., Olszewski J. Progressive supranuclear palsy: a heterogenous degeneration involving the brainstem, basal ganglia, and cerebellum with vertical gaze and pseudobulbar palsy, nuchal dystonia, and dementia. Archives of Neurology 1964; 10: 333–359
   PubMed Web of Science ®Google Scholar
• Sugden D., Morris R. D. Changes in regional brain levels of tryptophan, 5-hydroxytryptamine. 5-hydroxyindoleacetic acid, dopamine and noradrenaline after pinealectomy in the rat. Journal of Neurochemistry 1979; 32: 1593–1594
   PubMed Web of Science ®Google Scholar
• Trabulsi R., Pawlowski B., Wieraszko A. The influence of steady magnetic fields on the mouse hippocampal evoked potentials in vitro. Brain Research 1996; 728: 135–139
   PubMed Web of Science ®Google Scholar
• Vaughan G. M., McDonald S. D., Jordan R. M., Allen J. P., Bell R., Stevens E. A. Melatonin, pituitary functions and stress in humans. Psrchoneuroendocrinologv 1979; 4: 351–362
   PubMed Web of Science ®Google Scholar
• Vitte P. A., Harthe C., Lestage P., Claustrat B., Bobillier P. Plasma, cerebrospinal fluid, and brain distribution of 14C-melatonin in rat: A biochemical and autoradiographic study. Journal of Pineal Research 1988; 5: 437–453
   PubMed Web of Science ®Google Scholar
• Von Klitzing L. Low-frequency pulsed electromagnetic fields influence EEG on man. Physica Medico 1995; 11: 77–80
   Google Scholar
• Walleczek J. Electromagnetic field effect on cells on the immune system: the role of calcium signaling. Federation of the American Society of Experimental Biology (FASEB). Journal 1992; 6: 3177–3185
   Google Scholar
• Welker H. A., Semm P., Willig R. P., Commentz J. C., Wiltschko W., Vollrath L. Effects of an artifical magnetic field on serotonin N-acetyltransferase activity and melatonin content of the rat pineal gland. Experimental Brain Research 1983; 50: 426–432
   PubMed Web of Science ®Google Scholar
• Wendel O. T., Waterbury L. D., Pearce L. A. Increase in monoamine concentrations in rat brain following melatonin administration. Experientia 1974; 30: 1167–1168
   PubMedGoogle Scholar
• Wever R. Einfluss Schwacher Elektro-magnetischer Felder auf die Circadiane Periodik des Menschen. Naturwissenchaften 1968; 55: 29–32
   PubMed Web of Science ®Google Scholar
• Winikates J., Jankovic J. Vascular progressive supranuclear palsy. Journal of Neural Transmission 1994; 42: 189–201, suppl
   Google Scholar
• Yanagisawa N., Fujimoto S., Ueno E. Neurophysiological aspecys of Parkinson's disease. Current problems in treatment of Parkinson's disease, Y. Kuroiwa, Y. Toyokura. DMW, TokyoJapan 1985; 13–22
   Google Scholar